157 related articles for article (PubMed ID: 38630886)
1. LP-184, a Novel Acylfulvene Molecule, Exhibits Anticancer Activity against Diverse Solid Tumors with Homologous Recombination Deficiency.
Kulkarni A; Zhou J; Biyani N; Kathad U; Banerjee PP; Srivastava S; Prucsi Z; Solarczyk K; Bhatia K; Ewesuedo RB; Sharma P
Cancer Res Commun; 2024 May; 4(5):1199-1210. PubMed ID: 38630886
[TBL] [Abstract][Full Text] [Related]
2. LP-284, a small molecule acylfulvene, exerts potent antitumor activity in preclinical non-Hodgkin's lymphoma models and in cells deficient in DNA damage repair.
Zhou J; Sturtevant D; Love C; Kulkarni A; Biyani N; Kathad U; Thacker E; Dave S; Bhatia K
Oncotarget; 2023 Jun; 14():597-611. PubMed ID: 37306526
[TBL] [Abstract][Full Text] [Related]
3. Prexasertib treatment induces homologous recombination deficiency and synergizes with olaparib in triple-negative breast cancer cells.
Mani C; Jonnalagadda S; Lingareddy J; Awasthi S; Gmeiner WH; Palle K
Breast Cancer Res; 2019 Sep; 21(1):104. PubMed ID: 31492187
[TBL] [Abstract][Full Text] [Related]
4. Targeting homologous recombination deficiency in uterine leiomyosarcoma.
Dall G; Vandenberg CJ; Nesic K; Ratnayake G; Zhu W; Vissers JHA; Bedő J; Penington J; Wakefield MJ; Kee D; Carmagnac A; Lim R; Shield-Artin K; Milesi B; Lobley A; Kyran EL; O'Grady E; Tram J; Zhou W; Nugawela D; Stewart KP; Caldwell R; Papadopoulos L; Ng AP; Dobrovic A; Fox SB; McNally O; Power JD; Meniawy T; Tan TH; Collins IM; Klein O; Barnett S; Olesen I; Hamilton A; Hofmann O; Grimmond S; Papenfuss AT; Scott CL; Barker HE
J Exp Clin Cancer Res; 2023 May; 42(1):112. PubMed ID: 37143137
[TBL] [Abstract][Full Text] [Related]
5. YU238259 Is a Novel Inhibitor of Homology-Dependent DNA Repair That Exhibits Synthetic Lethality and Radiosensitization in Repair-Deficient Tumors.
Stachelek GC; Peterson-Roth E; Liu Y; Fernandez RJ; Pike LR; Qian JM; Abriola L; Hoyer D; Hungerford W; Merkel J; Glazer PM
Mol Cancer Res; 2015 Oct; 13(10):1389-97. PubMed ID: 26116172
[TBL] [Abstract][Full Text] [Related]
6. 53BP1 as a potential predictor of response in PARP inhibitor-treated homologous recombination-deficient ovarian cancer.
Hurley RM; Wahner Hendrickson AE; Visscher DW; Ansell P; Harrell MI; Wagner JM; Negron V; Goergen KM; Maurer MJ; Oberg AL; Meng XW; Flatten KS; De Jonge MJA; Van Herpen CD; Gietema JA; Koornstra RHT; Jager A; den Hollander MW; Dudley M; Shepherd SP; Swisher EM; Kaufmann SH
Gynecol Oncol; 2019 Apr; 153(1):127-134. PubMed ID: 30686551
[TBL] [Abstract][Full Text] [Related]
7. ATR Inhibition Is a Promising Radiosensitizing Strategy for Triple-Negative Breast Cancer.
Tu X; Kahila MM; Zhou Q; Yu J; Kalari KR; Wang L; Harmsen WS; Yuan J; Boughey JC; Goetz MP; Sarkaria JN; Lou Z; Mutter RW
Mol Cancer Ther; 2018 Nov; 17(11):2462-2472. PubMed ID: 30166399
[TBL] [Abstract][Full Text] [Related]
8. Conditional Dependency of LP-184 on Prostaglandin Reductase 1 is Synthetic Lethal in Pancreatic Cancers with DNA Damage Repair Deficiencies.
Restifo D; McDermott JR; Cvetkovic D; Dos Santos T; Ogier C; Surumbayeva A; Handorf EA; Schimke C; Ma C; Cai KQ; Olszanski AJ; Kathad U; Bhatia K; Sharma P; Kulkarni A; Astsaturov I
Mol Cancer Ther; 2023 Oct; 22(10):1182-1190. PubMed ID: 37552607
[TBL] [Abstract][Full Text] [Related]
9. FEN1 endonuclease as a therapeutic target for human cancers with defects in homologous recombination.
Guo E; Ishii Y; Mueller J; Srivatsan A; Gahman T; Putnam CD; Wang JYJ; Kolodner RD
Proc Natl Acad Sci U S A; 2020 Aug; 117(32):19415-19424. PubMed ID: 32719125
[TBL] [Abstract][Full Text] [Related]
10. DNA-Damage-Repair Gene Alterations in Genitourinary Malignancies.
Dariane C; Timsit MO
Eur Surg Res; 2022; 63(4):155-164. PubMed ID: 35944490
[TBL] [Abstract][Full Text] [Related]
11. Curcumin suppresses multiple DNA damage response pathways and has potency as a sensitizer to PARP inhibitor.
Ogiwara H; Ui A; Shiotani B; Zou L; Yasui A; Kohno T
Carcinogenesis; 2013 Nov; 34(11):2486-97. PubMed ID: 23825154
[TBL] [Abstract][Full Text] [Related]
12. PARP inhibitor synthetic lethality in ATM biallelic mutant cancer cell lines is associated with BRCA1/2 and RAD51 downregulation.
Muvaffak A; Coleman KG
Front Oncol; 2024; 14():1380633. PubMed ID: 38807759
[TBL] [Abstract][Full Text] [Related]
13. Homologous recombination deficiency (HRD) status predicts response to standard neoadjuvant chemotherapy in patients with triple-negative or BRCA1/2 mutation-associated breast cancer.
Telli ML; Hellyer J; Audeh W; Jensen KC; Bose S; Timms KM; Gutin A; Abkevich V; Peterson RN; Neff C; Hughes E; Sangale Z; Jones J; Hartman AR; Chang PJ; Vinayak S; Wenstrup R; Ford JM
Breast Cancer Res Treat; 2018 Apr; 168(3):625-630. PubMed ID: 29275435
[TBL] [Abstract][Full Text] [Related]
14. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
[TBL] [Abstract][Full Text] [Related]
15. The BET inhibitor INCB054329 reduces homologous recombination efficiency and augments PARP inhibitor activity in ovarian cancer.
Wilson AJ; Stubbs M; Liu P; Ruggeri B; Khabele D
Gynecol Oncol; 2018 Jun; 149(3):575-584. PubMed ID: 29567272
[TBL] [Abstract][Full Text] [Related]
16. Quantitative measurement of alterations in DNA damage repair (DDR) pathways using single cell network profiling (SCNP).
Rosen DB; Leung LY; Louie B; Cordeiro JA; Conroy A; Shapira I; Fields SZ; Cesano A; Hawtin RE
J Transl Med; 2014 Jun; 12():184. PubMed ID: 24965603
[TBL] [Abstract][Full Text] [Related]
17. New Targeted Agents in Gynecologic Cancers: Synthetic Lethality, Homologous Recombination Deficiency, and PARP Inhibitors.
Liu FW; Tewari KS
Curr Treat Options Oncol; 2016 Mar; 17(3):12. PubMed ID: 26931795
[TBL] [Abstract][Full Text] [Related]
18. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
19. Synthetic Lethality Exploitation by an Anti-Trop-2-SN-38 Antibody-Drug Conjugate, IMMU-132, Plus PARP Inhibitors in
Cardillo TM; Sharkey RM; Rossi DL; Arrojo R; Mostafa AA; Goldenberg DM
Clin Cancer Res; 2017 Jul; 23(13):3405-3415. PubMed ID: 28069724
[No Abstract] [Full Text] [Related]
20. Cracking the homologous recombination deficiency code: how to identify responders to PARP inhibitors.
Paulet L; Trecourt A; Leary A; Peron J; Descotes F; Devouassoux-Shisheboran M; Leroy K; You B; Lopez J
Eur J Cancer; 2022 May; 166():87-99. PubMed ID: 35279473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
